Cel-Sci Corporation (NYSEAMERICAN:CVM – Get Free Report)’s share price dropped 2.1% during mid-day trading on Wednesday. The company traded as low as $1.38 and last traded at $1.38. Approximately 27,787 shares were traded during trading, a decline of 85% from the average session volume of 183,912 shares. The stock had previously closed at $1.41.
Cel-Sci Stock Performance
The stock has a 50-day moving average price of $1.70 and a 200 day moving average price of $2.49. The company has a quick ratio of 1.42, a current ratio of 1.48 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $24.12 million, a price-to-earnings ratio of -0.14 and a beta of 0.62.
Cel-Sci (NYSEAMERICAN:CVM – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter.
Institutional Trading of Cel-Sci
An institutional investor recently raised its position in Cel-Sci stock. Renaissance Technologies LLC lifted its stake in shares of Cel-Sci Corporation (NYSEAMERICAN:CVM – Free Report) by 133.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 35,890 shares of the company’s stock after buying an additional 20,484 shares during the quarter. Renaissance Technologies LLC owned about 0.42% of Cel-Sci worth $115,000 at the end of the most recent reporting period. 12.08% of the stock is owned by institutional investors and hedge funds.
About Cel-Sci
Cel-Sci Corporation is a biotechnology company focused on developing investigational immunotherapies for cancer and infectious diseases. The company’s lead product candidate, Multikine (leukocyte interleukin, injection), is designed to stimulate and coordinate the immune system’s response to cancer. It has primarily been studied as a potential treatment for locally advanced primary head and neck cancer and is not an approved commercial therapy.
Cel-Sci also develops treatments using its proprietary LEAPS (L.E.A.P.S.) technology platform, which is intended to direct immune responses against specific disease-related targets.
Recommended Stories
- Five stocks we like better than Cel-Sci
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Cel-Sci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cel-Sci and related companies with MarketBeat.com's FREE daily email newsletter.
